[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome
NCT ID: NCT05017844
Last Updated: 2021-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
222 participants
INTERVENTIONAL
2020-02-18
2021-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001
NCT05017870
Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.
NCT03723798
Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group
NCT01768312
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
NCT02092207
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
NCT05403827
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KSR-001-04
KSR-001-04 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
KSR-001-04
One drop to both eyes four times a day for 12 weeks
KSR-001-02
KSR-001-02 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
KSR-001-02
One drop to both eyes four times a day for 12 weeks
KSR-001-03
KSR-001-03 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
KSR-001-03
One drop to both eyes four times a day for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KSR-001-04
One drop to both eyes four times a day for 12 weeks
KSR-001-02
One drop to both eyes four times a day for 12 weeks
KSR-001-03
One drop to both eyes four times a day for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Those who have had symptoms of dry eye for at least 6 months (foreign body sensation, dryness, glare, pain pain, blurred vision, etc.) and Those whose symptoms do not improve with conservative treatment such as artificial tears
3. Those who meet below criteria at least one of two eyes
* Those who have over than score 4 in corneal staining test
* Tear secretion test without anesthesia(Schirmer test) result would be under 10mm/5min (If the test result is 0mm/5min, it should be over than 3mm/5min on the nasal stimulation schirmer test in the same eye)
4. both eyes, the corrected visual acuity is 0.2 or more
5. Written consent voluntarily to participate in this clinical trial
Exclusion Criteria
2. Within 90 days of the screening visit, if systemic steroid steroids or systemic immunosuppressants were used
3. Within 90 days of the screening visit, If there is a history of other ophthalmic surgeries including the use of punctum plugs or puncture closure surgery
4. If it is a clinically significant ophthalmic disease that is not caused by dry eye syndrome and may affect the interpretation of the results of this clinical trial
5. Within 90 days of the screening visit, Those who have undergone vision correction surgery such as LASIK or LASIK
6. Those with intraocular pressure (IOP) exceeding 21 mmHg or with glaucoma undergoing drug treatment
7. Those with hypersensitivity to the ingredient of this clinical trial drug
8. Patients planning to wear contact lenses during the clinical trial period
9. In the case of one of the following
* Creatinine level more than twice the upper limit of normal range
* AST or ALT levels greater than twice the upper limit of normal range
10. History of malignancy (except for cases where there has been no recurrence for more than 5 years after surgery)
11. Within 1 year before screening, Those who have been diagnosed with alcohol or drug abuse and are receiving treatment
12. In the case of women of childbearing potential, those who do not consent to contraception by a medically accepted method of contraception during the clinical trial period (IUD, Intrauterine device or IUS, Intrauterine system), tubal ligation, double blocking method (male condom, female condoms, cervical caps, contraceptive diaphragms, and Combination of blocking methods such as contraceptive sponges)
13. Pregnant or lactating women
14. within 30 days before participating in the clinical trial, Those who have applied other clinical trial drugs or medical devices
15. Patients judged by other investigators as unsuitable to participate in this clinical trial
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samil Pharmaceutical Co., Ltd.
INDUSTRY
Kukje Pharma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kukje Pharma
Seongnam, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KSR-001-P02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.